Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis

Severe aortic stenosis (AS) is the most common valvular heart disease with a prevalence rate of more than 4% in 75-year-old people or older. Similarly, cardiac amyloidosis (CA), especially “wild-type transthyretin” (wTTR), has shown a prevalence rate ranging from 22% to 25% in people older than 80 years. The detection of the concomitant presence of CA and AS is challenging primarily because of the similar type of changes in the left ventricle caused by AS and CA, which share some morphological characteristics. The aim of this review is to identify the imaging triggers in order to recognize occult wtATTR-CA in patients with AS, clarifying the crucial step of the diagnostic process. Multimodality imaging methods such as echocardiography, cardiac magnetic resonance, cardiac computed tomography, and DPD scintigraphy will be analyzed as part of the available diagnostic workup to identify wtATTR-CA early in patients with AS.

[1]  M. Emdin,et al.  N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis , 2023 .

[2]  A. Cohen-Solal,et al.  NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis. , 2022, European journal of heart failure.

[3]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). , 2022, Revista espanola de cardiologia.

[4]  M. Emdin,et al.  Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies , 2022, European journal of heart failure.

[5]  G. Parati,et al.  Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey , 2022, European journal of heart failure.

[6]  Germany,et al.  Corrigendum to: 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). , 2022, European heart journal.

[7]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[8]  M. Henein,et al.  Aortic Valve Stenosis and Cardiac Amyloidosis: A Misleading Association , 2021, Journal of clinical medicine.

[9]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.

[10]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[11]  D. Carrié,et al.  Value of Longitudinal Strain to Identify Wild-Type Transthyretin Amyloidosis in Patients With Aortic Stenosis. , 2021, Circulation journal : official journal of the Japanese Circulation Society.

[12]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[13]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases , 2021, European journal of heart failure.

[14]  M. Emdin,et al.  A simple echocardiographic score to rule out cardiac amyloidosis , 2020, European journal of clinical investigation.

[15]  T. Tan,et al.  The Role of Multi-modality Imaging in the Diagnosis of Cardiac Amyloidosis: A Focused Update , 2020, Frontiers in Cardiovascular Medicine.

[16]  E. Klotz,et al.  Identifying Cardiac Amyloid in Aortic Stenosis , 2020, JACC. Cardiovascular imaging.

[17]  C. Di Mario,et al.  Cardiac amyloidosis in patient undergoing TAVR, why we need to think about it. , 2020, Cardiovascular revascularization medicine : including molecular interventions.

[18]  E. Klotz,et al.  DPD Quantification in Cardiac Amyloidosis , 2020, JACC. Cardiovascular imaging.

[19]  C. Rapezzi,et al.  Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. , 2020, European heart journal cardiovascular Imaging.

[20]  A. Masri,et al.  Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis , 2020, European journal of heart failure.

[21]  C. Loewe,et al.  Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome , 2020, European journal of heart failure.

[22]  J. Moon,et al.  Identifying Cardiac Amyloid in Aortic Stenosis: ECV Quantification by CT in TAVR Patients , 2020 .

[23]  G. Pontone,et al.  Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[24]  C. Autore,et al.  Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[25]  Z. Prohászka,et al.  Coexistence of aortic valve stenosis and cardiac amyloidosis: echocardiographic and clinical significance , 2019, Cardiovascular Ultrasound.

[26]  P. Pibarot,et al.  Aortic Stenosis and Cardiac Amyloidosis: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[27]  A. Aidietis,et al.  Transthyretin cardiac amyloidosis in aortic stenosis: prevalence, diagnostic challenges and clinical implications. , 2019, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[28]  P. Elliott,et al.  Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta‐analysis , 2019, ESC heart failure.

[29]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[30]  M. Dweck,et al.  Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis. , 2019, JACC. Cardiovascular imaging.

[31]  Y. Yamashita,et al.  Myocardial Late Iodine Enhancement and Extracellular Volume Quantification with Dual-Layer Spectral Detector Dual-Energy Cardiac CT. , 2019, Radiology. Cardiothoracic imaging.

[32]  M. Desai,et al.  Distribution and Prognostic Significance of Left Ventricular Global Longitudinal Strain in Asymptomatic Significant Aortic Stenosis: An Individual Participant Data Meta-Analysis. , 2019, JACC. Cardiovascular imaging.

[33]  Sanjay K. Prasad,et al.  Myocardial Scar and Mortality in Severe Aortic Stenosis , 2018, Circulation.

[34]  J. Moon,et al.  Cardiac amyloidosis in aortic stenosis: The tip of the iceberg. , 2018, The Journal of thoracic and cardiovascular surgery.

[35]  M. Maurer,et al.  Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. , 2018, Journal of cardiac failure.

[36]  M. Galderisi,et al.  Echocardiographic advances in hypertrophic cardiomyopathy: Three‐dimensional and strain imaging echocardiography , 2018, Echocardiography.

[37]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[38]  A. Luciani,et al.  Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study , 2018, European Radiology.

[39]  D. Forman,et al.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis , 2017, Journal of Cardiovascular Magnetic Resonance.

[40]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[41]  B. Wintersperger,et al.  Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics , 2017, Journal of Cardiovascular Magnetic Resonance.

[42]  P. Kellman,et al.  Magnetic Resonance in Transthyretin Cardiac Amyloidosis. , 2017, Journal of the American College of Cardiology.

[43]  S. Punwani,et al.  Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: Synthetic ECV by CCT. , 2017, Journal of cardiovascular computed tomography.

[44]  D. Pennell,et al.  Midwall Fibrosis and 5-Year Outcome in Moderate and Severe Aortic Stenosis. , 2017, Journal of the American College of Cardiology.

[45]  D. Bergqvist,et al.  A population-based autopsy study , 2017 .

[46]  C. Tribouilloy,et al.  Usefulness of 3-Tesla cardiac magnetic resonance imaging in the assessment of aortic stenosis severity in routine clinical practice. , 2016, Archives of cardiovascular diseases.

[47]  S. K. White,et al.  Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. , 2016, Circulation. Cardiovascular imaging.

[48]  G. Dattilo,et al.  Left Atrial Morphology, Size and Function in Patients With Transthyretin Cardiac Amyloidosis and Primary Hypertrophic Cardiomyopathy - Comparative Strain Imaging Study. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[49]  W. Jaber,et al.  Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis. , 2016, JACC. Cardiovascular imaging.

[50]  William Y S Wang,et al.  Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study , 2016, The Journal of Nuclear Medicine.

[51]  S. Heymans,et al.  Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.

[52]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[53]  C. Rapezzi,et al.  Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. , 2016, JACC. Cardiovascular imaging.

[54]  J. Dubois-Randé,et al.  Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? , 2016, European Heart Journal.

[55]  V. S. Misleading association , 2016, BDJ.

[56]  S. Punwani,et al.  Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis , 2015, Journal of cardiovascular computed tomography.

[57]  P. Kellman,et al.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2015, Circulation.

[58]  R. Falk,et al.  18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study , 2015, Circulation. Cardiovascular imaging.

[59]  J. Moon,et al.  Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. , 2015, Radiology.

[60]  A. Luciani,et al.  Noninvasive detection of cardiac amyloidosis using delayed enhanced MDCT: a pilot study , 2015, European Radiology.

[61]  Michael J.A. Williams,et al.  The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis. , 2014, Journal of the American College of Cardiology.

[62]  B. Hazenberg,et al.  Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[63]  L. Anderson,et al.  CMR-based differentiation of AL and ATTR cardiac amyloidosis. , 2014, JACC. Cardiovascular imaging.

[64]  M. Bursztyn Impact on Prognosis , 2014 .

[65]  B. Bijnens,et al.  Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis From Other Causes of Concentric Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular imaging.

[66]  A. Bogers,et al.  Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. , 2013, Journal of the American College of Cardiology.

[67]  M. Lubberink,et al.  In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.

[68]  G. Nguyen Tip of the iceberg? , 2012, Gut microbes.

[69]  James D. Thomas,et al.  Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis , 2012, Heart.

[70]  E. V. van Beek,et al.  Assessment of Valvular Calcification and Inflammation by Positron Emission Tomography in Patients With Aortic Stenosis , 2012, Circulation.

[71]  F. Salvi,et al.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.

[72]  P. Limburg,et al.  Diagnostic performance of transthyretin measurement in fat tissue of patients with ATTR amyloidosis , 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[73]  C. Rochitte,et al.  Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. , 2010, Journal of the American College of Cardiology.

[74]  Matthew W. Martinez,et al.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. , 2010, JACC. Cardiovascular imaging.

[75]  A. Singleton,et al.  Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study , 2008, Annals of medicine.

[76]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[77]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[78]  It Istituto Superiore di Sanit,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .

[79]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[80]  R A Kyle,et al.  Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.

[81]  DPD Quanti fi cation in Cardiac Amyloidosis A Novel Imaging Biomarker , 2022 .